Akhil Anand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akhil Anand has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Jeremy Weleff
Department of Psychiatry, University of Alberta, Canada; Department of Psychiatry, Yale School of Medicine, USA
11 shared publications - Brian Scott Barnett
Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
6 shared publications - Gabriel . P. A. Costa
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States
6 shared publications - Daniel Lacerda Heringer
Department of Psychiatry and Psychology Cleveland Clinic Cleveland Ohio USA
4 shared publications Jeremy Weleff
Department of Psychiatry, University of Alberta, 4-142 Katz Group Centre for Pharmacy and Health Research, Edmonton, Alberta T6G 2R3, Canada; Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT 06511, USA
4 shared publications- Minahil Iqbal
Allama Iqbal Medical College Lahore Pakistan
3 shared publications
Latest Publications
- 18 September 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Efficacy and Tolerability of Zonisamide for Alcohol Use Disorder
Purpose: Zonisamide, an anticonvulsant with GABAergic and glutamatergic effects, has been investigated as a treatment for alcohol use disorder (AUD), but its efficacy and tolerability remain uncertain. This systematic review and meta-analysis synthesizes evidence from randomized controlled trials evaluating zonisamide for AUD. Procedures: We searched MEDLINE, Embase, PsycINFO, Scopus, and CENTRAL from inception through June 23, 2025, with an updated search on March 31, 2026, for randomized controlled trials comparing zonisamide to placebo in adults with AUD. The primary outcome was a reduction in alcohol use. Data were pooled using random-effects meta-analyses. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Findings: Five randomized controlled trials (N=344) met inclusion criteria. Zonisamide significantly reduced drinks per day (MD=−0.79; 95% CI=−0.95 to −0.63; P P P =0.11), with high heterogeneity ( I ²=91%). Zonisamide was associated with a significantly lower rate of nervousness, anxiety, or irritability (RR=0.53; 95% CI=0.34-0.84; P =0.007); other adverse events did not differ from placebo. Implications: Zonisamide reduced drinks per day and drinking days but not heavy drinking days, suggesting a selective benefit on overall consumption. A protective effect on nervousness, anxiety, and irritability was also observed, consistent with zonisamide’s GABAergic mechanism. Further well-powered trials are needed to inform clinical recommendations.
- 18 September 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Efficacy and Tolerability of Zonisamide for Alcohol Use Disorder
Purpose: Zonisamide, an anticonvulsant with GABAergic and glutamatergic effects, has been investigated as a treatment for alcohol use disorder (AUD), but its efficacy and tolerability remain uncertain. This systematic review and meta-analysis synthesizes evidence from randomized controlled trials evaluating zonisamide for AUD. Procedures: We searched MEDLINE, Embase, PsycINFO, Scopus, and CENTRAL from inception through June 23, 2025, with an updated search on March 31, 2026, for randomized controlled trials comparing zonisamide to placebo in adults with AUD. The primary outcome was a reduction in alcohol use. Data were pooled using random-effects meta-analyses. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Findings: Five randomized controlled trials (N=344) met inclusion criteria. Zonisamide significantly reduced drinks per day (MD=−0.79; 95% CI=−0.95 to −0.63; P P P =0.11), with high heterogeneity ( I ²=91%). Zonisamide was associated with a significantly lower rate of nervousness, anxiety, or irritability (RR=0.53; 95% CI=0.34-0.84; P =0.007); other adverse events did not differ from placebo. Implications: Zonisamide reduced drinks per day and drinking days but not heavy drinking days, suggesting a selective benefit on overall consumption. A protective effect on nervousness, anxiety, and irritability was also observed, consistent with zonisamide’s GABAergic mechanism. Further well-powered trials are needed to inform clinical recommendations.
- Open Access
- 25 August 2026
- Published by Springer Nature in AIDS and Behavior
- p. 1-6
Trends in Buprenorphine Prescribing Among Adults with Opioid Use Disorder and Coexisting HIV or Viral Hepatitis, 2015–2025
We examined buprenorphine prescribing among adults in the United States with opioid use disorder or other opioid-related diagnoses and coexisting HIV, hepatitis B, or hepatitis C from 2015 to 2025. Using the TriNetX USA Minimal Date Shift Network, we constructed annual cohorts and assessed encounter-day buprenorphine prescribing, with and without chronic pain diagnoses. Prescribing rose from 6% in 2015 to 17% in 2020, then plateaued at 16–19% through 2025, with marked attenuation after 2020. Despite expanded prescriber eligibility, most were not prescribed buprenorphine at clinical contact, suggesting regulatory reform alone is insufficient and that integrated, systemic approaches are needed.
- 25 August 2026
- Published by Springer Nature in AIDS and Behavior
- p. 1-6
Open AccessTrends in Buprenorphine Prescribing Among Adults with Opioid Use Disorder and Coexisting HIV or Viral Hepatitis, 2015–2025
We examined buprenorphine prescribing among adults in the United States with opioid use disorder or other opioid-related diagnoses and coexisting HIV, hepatitis B, or hepatitis C from 2015 to 2025. Using the TriNetX USA Minimal Date Shift Network, we constructed annual cohorts and assessed encounter-day buprenorphine prescribing, with and without chronic pain diagnoses. Prescribing rose from 6% in 2015 to 17% in 2020, then plateaued at 16–19% through 2025, with marked attenuation after 2020. Despite expanded prescriber eligibility, most were not prescribed buprenorphine at clinical contact, suggesting regulatory reform alone is insufficient and that integrated, systemic approaches are needed.
- 13 August 2026
- Published by Taylor & Francis in Journal of Addictive Diseases
- p. 1-7
Adjunctive oral naltrexone for breakthrough craving in patients receiving extended-release injectable naltrexone for alcohol use disorder: Three cases
Craving is a subjective, poorly characterized phenomenon that is central to return to use in individuals with substance use disorder (1). Effectively addressing craving remains a critical challenge...
- 13 August 2026
- Published by Taylor & Francis in Journal of Addictive Diseases
- p. 1-7
Adjunctive oral naltrexone for breakthrough craving in patients receiving extended-release injectable naltrexone for alcohol use disorder: Three cases
Craving is a subjective, poorly characterized phenomenon that is central to return to use in individuals with substance use disorder (1). Effectively addressing craving remains a critical challenge...
- Open Access
- 14 July 2026
- Published by Springer Nature in Academic Psychiatry
- p. 1-6
A Citywide Collaboration to Expand Addiction Psychiatry Training: Development of a Multi-institution Fellowship Model
- 14 July 2026
- Published by Springer Nature in Academic Psychiatry
- p. 1-6
Open AccessA Citywide Collaboration to Expand Addiction Psychiatry Training: Development of a Multi-institution Fellowship Model
- 22 June 2026
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 22 (3) , 1-9
Suicide-Related Mortality Among Individuals with Mental and Behavioral Disorders Due to Psychoactive Substance Use: A 25-Year U.S. Nationwide Analysis (1999–2023)
Objective: Mental and behavioral disorders due to psychoactive substance use, as defined by ICD-10 codes F10-F19, include a spectrum of substance use disorders such as acute intoxication, withdrawal, harmful use, and dependence related to alcohol, opioids, stimulants, cannabis, tobacco, and other substances. These conditions significantly increase the risk of suicide, yet national trends in suicide-related mortality among affected individuals remain underexplored. This study aimed to evaluate national trends in suicide and self-harm mortality among individuals with these disorders from 1999 to 2023. Methods: We conducted a retrospective analysis of U.S. death certificate data from the CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) database (1999-2023). Decedents with mental and behavioral disorders due to psychoactive substance use were identified using ICD-10 codes F10-F19, encompassing acute intoxication, withdrawal, harmful use, and dependence. Suicide and self-harm deaths were defined by ICD-10 codes U03, X60-X84, and Y87. Age-adjusted mortality rates (AAMRs) per million and average annual percentage changes (AAPCs) were estimated using Joinpoint regression. Analyses were stratified by sex, age, race/ethnicity, and metropolitan status. Results: Between 1999 and 2023, 37,473 suicide-related deaths were identified among U.S. individuals with mental and behavioral disorders due to psychoactive substance use. AAMRs increased from 2.2 to 5.7 per million (AAPC: 3.31; p < .01). Males had higher mortality than females (6.6 vs. 2.9), though females had a steeper rate of increase over time. Middle-aged adults had the highest AAMR (8.2), followed by younger (6.9), older adults (3.4) and children and adolescents (1.1). Non-Hispanic (NH) American Indian/Alaska Native individuals (AI/AN) had the highest AAMR (13.5), followed by NH White (6.2), Hispanic/Latino (1.6), NH Black (1.6), and NH Asian/Pacific Islander (API) (1.4). From 1999 to 2000, non-metropolitan areas had higher AAMRs than metropolitan areas (6.5 vs. 4.3), with significant increases in both settings. Conclusions: Suicide-related mortality among individuals with mental and behavioral disorders due to psychoactive substance use has increased significantly increased in the United States from 1999 to 2023, demonstrating substantial disparities by sex, age, race/ethnicity, and geographic region. These findings highlight the critical need for integrated approaches in suicide prevention and substance-related treatment settings.
- 22 June 2026
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 22 (3) , 1-9
Suicide-Related Mortality Among Individuals with Mental and Behavioral Disorders Due to Psychoactive Substance Use: A 25-Year U.S. Nationwide Analysis (1999–2023)
Objective: Mental and behavioral disorders due to psychoactive substance use, as defined by ICD-10 codes F10-F19, include a spectrum of substance use disorders such as acute intoxication, withdrawal, harmful use, and dependence related to alcohol, opioids, stimulants, cannabis, tobacco, and other substances. These conditions significantly increase the risk of suicide, yet national trends in suicide-related mortality among affected individuals remain underexplored. This study aimed to evaluate national trends in suicide and self-harm mortality among individuals with these disorders from 1999 to 2023. Methods: We conducted a retrospective analysis of U.S. death certificate data from the CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) database (1999-2023). Decedents with mental and behavioral disorders due to psychoactive substance use were identified using ICD-10 codes F10-F19, encompassing acute intoxication, withdrawal, harmful use, and dependence. Suicide and self-harm deaths were defined by ICD-10 codes U03, X60-X84, and Y87. Age-adjusted mortality rates (AAMRs) per million and average annual percentage changes (AAPCs) were estimated using Joinpoint regression. Analyses were stratified by sex, age, race/ethnicity, and metropolitan status. Results: Between 1999 and 2023, 37,473 suicide-related deaths were identified among U.S. individuals with mental and behavioral disorders due to psychoactive substance use. AAMRs increased from 2.2 to 5.7 per million (AAPC: 3.31; p < .01). Males had higher mortality than females (6.6 vs. 2.9), though females had a steeper rate of increase over time. Middle-aged adults had the highest AAMR (8.2), followed by younger (6.9), older adults (3.4) and children and adolescents (1.1). Non-Hispanic (NH) American Indian/Alaska Native individuals (AI/AN) had the highest AAMR (13.5), followed by NH White (6.2), Hispanic/Latino (1.6), NH Black (1.6), and NH Asian/Pacific Islander (API) (1.4). From 1999 to 2000, non-metropolitan areas had higher AAMRs than metropolitan areas (6.5 vs. 4.3), with significant increases in both settings. Conclusions: Suicide-related mortality among individuals with mental and behavioral disorders due to psychoactive substance use has increased significantly increased in the United States from 1999 to 2023, demonstrating substantial disparities by sex, age, race/ethnicity, and geographic region. These findings highlight the critical need for integrated approaches in suicide prevention and substance-related treatment settings.
- 12 May 2026
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 285, 113196
Tianeptine misuse and addiction: A systematic review of withdrawal, toxicity, and clinical management
- 12 May 2026
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 285, 113196
Tianeptine misuse and addiction: A systematic review of withdrawal, toxicity, and clinical management
- 7 April 2026
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 34 (4) , 747-753
Risk of Non-Infectious Uveitis Associated with Medications for Substance Use Disorders
Substance use disorders (SUD) are associated with various ocular pathologies, ranging from ocular surface dryness to severe conditions such as vascular occlusion.1 SUD can be treated with a heterog...
- 7 April 2026
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 34 (4) , 747-753
Risk of Non-Infectious Uveitis Associated with Medications for Substance Use Disorders
Substance use disorders (SUD) are associated with various ocular pathologies, ranging from ocular surface dryness to severe conditions such as vascular occlusion.1 SUD can be treated with a heterog...
- Top Cited Papers
- 19 January 2026
- Published by Springer Nature in CNS Drugs
- Vol. 40 (3) , 419-449
Clinical Presentations and Treatment of Baclofen Toxicity and Withdrawal: A Systematic Review
Background Baclofen is a γ-aminobutyric acid type B receptor agonist primarily used for spasticity. It is increasingly prescribed orally at high off-label doses for conditions such as alcohol use disorder, raising concerns regarding severe toxicity and withdrawal syndromes. This systematic review comprehensively characterizes the clinical presentations, management strategies, and outcomes associated with oral baclofen toxicity and withdrawal. Methods MEDLINE, Embase, and CENTRAL databases were searched from inception through October 2024. Eligible studies included clinical trials, observational studies, case series, and case reports describing oral baclofen toxicity or withdrawal in humans. Excluded were studies on intrathecal baclofen, non-human or preclinical data, gray literature, and reports lacking sufficient clinical data. Three reviewers independently performed study screening, data extraction, and quality assessments. The Joanna Briggs Institute Critical Appraisal Checklists for case reports, case series, and observational studies were used to evaluate methodological quality and risk of bias across included studies. Discrepancies were resolved by consensus among reviewers, with senior author verification when needed. Outcome measures included clinical presentation, management strategies, need for intensive care or mechanical ventilation, length of hospital stay, recovery status, and mortality. Because of study heterogeneity, data were synthesized narratively without a formal certainty assessment. Results Sixty-six case reports (44 toxicity cases from 38 case reports, 34 withdrawal cases from 28 case reports) and 18 retrospective studies (n = 1540) were included (total n = 1618 individuals). Baclofen toxicity commonly presented with central nervous system depression (68%), seizures (36%), and respiratory depression (21%), particularly at doses ≥ 300 mg. Management predominantly involved supportive measures, including mechanical ventilation in approximately 54.5% of cases. Full clinical recovery occurred in 97.7% of cases. In retrospective cohorts, mortality was generally low (~ 0–4%), with most patients recovering following supportive management. Baclofen withdrawal commonly manifested with severe psychiatric disturbances (up to 20.6%), delirium, agitation, and autonomic instability, typically emerging within 1–4 days after abrupt discontinuation. Rapid baclofen reinitiation consistently resolved withdrawal symptoms. Conclusions Baclofen toxicity and withdrawal can become severe or life threatening, underscoring the need for prompt recognition and careful medical management. Clinicians should exercise caution when prescribing baclofen, particularly at higher doses (≥ 300 mg/day). Prospective studies and standardized clinical guidelines are needed to enhance patient safety and optimize outcomes. PROSPERO number CRD420251155708.
- 19 January 2026
- Published by Springer Nature in CNS Drugs
- Vol. 40 (3) , 419-449
Top Cited PapersClinical Presentations and Treatment of Baclofen Toxicity and Withdrawal: A Systematic Review
Background Baclofen is a γ-aminobutyric acid type B receptor agonist primarily used for spasticity. It is increasingly prescribed orally at high off-label doses for conditions such as alcohol use disorder, raising concerns regarding severe toxicity and withdrawal syndromes. This systematic review comprehensively characterizes the clinical presentations, management strategies, and outcomes associated with oral baclofen toxicity and withdrawal. Methods MEDLINE, Embase, and CENTRAL databases were searched from inception through October 2024. Eligible studies included clinical trials, observational studies, case series, and case reports describing oral baclofen toxicity or withdrawal in humans. Excluded were studies on intrathecal baclofen, non-human or preclinical data, gray literature, and reports lacking sufficient clinical data. Three reviewers independently performed study screening, data extraction, and quality assessments. The Joanna Briggs Institute Critical Appraisal Checklists for case reports, case series, and observational studies were used to evaluate methodological quality and risk of bias across included studies. Discrepancies were resolved by consensus among reviewers, with senior author verification when needed. Outcome measures included clinical presentation, management strategies, need for intensive care or mechanical ventilation, length of hospital stay, recovery status, and mortality. Because of study heterogeneity, data were synthesized narratively without a formal certainty assessment. Results Sixty-six case reports (44 toxicity cases from 38 case reports, 34 withdrawal cases from 28 case reports) and 18 retrospective studies (n = 1540) were included (total n = 1618 individuals). Baclofen toxicity commonly presented with central nervous system depression (68%), seizures (36%), and respiratory depression (21%), particularly at doses ≥ 300 mg. Management predominantly involved supportive measures, including mechanical ventilation in approximately 54.5% of cases. Full clinical recovery occurred in 97.7% of cases. In retrospective cohorts, mortality was generally low (~ 0–4%), with most patients recovering following supportive management. Baclofen withdrawal commonly manifested with severe psychiatric disturbances (up to 20.6%), delirium, agitation, and autonomic instability, typically emerging within 1–4 days after abrupt discontinuation. Rapid baclofen reinitiation consistently resolved withdrawal symptoms. Conclusions Baclofen toxicity and withdrawal can become severe or life threatening, underscoring the need for prompt recognition and careful medical management. Clinicians should exercise caution when prescribing baclofen, particularly at higher doses (≥ 300 mg/day). Prospective studies and standardized clinical guidelines are needed to enhance patient safety and optimize outcomes. PROSPERO number CRD420251155708.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Psychiatry
- Vol. 2026 (1) , 1043995
Near Total Resolution of Severe Refractory Chronic Cough With Low‐Dose Sublingual Buprenorphine: Case Report
Refractory or unexplained chronic cough (RUCC) is a cough lasting more than 8 weeks that persists despite guidelines‐based evaluation and treatment, either because no cause is identified or because the cough continues after appropriate treatment of identified conditions. It can significantly impair functioning, sleep, and quality of life. Guideline‐supported options remain limited. We report on a case of RUCC that was very effectively treated with low‐dose sublingual buprenorphine. This partial μ‐opioid agonist can offer greater safety and lower misuse liability compared to full opioid agonists or tramadol. Further study of this treatment option is warranted.
- 1 January 2026
- Published by Wiley in Case Reports in Psychiatry
- Vol. 2026 (1) , 1043995
Open AccessNear Total Resolution of Severe Refractory Chronic Cough With Low‐Dose Sublingual Buprenorphine: Case Report
Refractory or unexplained chronic cough (RUCC) is a cough lasting more than 8 weeks that persists despite guidelines‐based evaluation and treatment, either because no cause is identified or because the cough continues after appropriate treatment of identified conditions. It can significantly impair functioning, sleep, and quality of life. Guideline‐supported options remain limited. We report on a case of RUCC that was very effectively treated with low‐dose sublingual buprenorphine. This partial μ‐opioid agonist can offer greater safety and lower misuse liability compared to full opioid agonists or tramadol. Further study of this treatment option is warranted.
- 4 November 2025
- Published by Wiley in The American Journal on Addictions
- Vol. 35 (3) , 362-369
Readability, linguistic complexity, and stigma in ChatGPT responses to opioid use disorder FAQs: A comparative analysis
Background and Objectives: AI chatbots are increasingly used in patient education. For opioid use disorder (OUD), content must be readable and non‐stigmatizing. We compared ChatGPT responses with U.S. health organization FAQs on readability, complexity, and stigma. Methods: We analyzed 50 OUD FAQs paired with ChatGPT GPT‐4o responses. Outcomes included word and sentence counts, lexical density, and six readability indices. Paired differences were tested with t tests or Wilcoxon signed‐rank tests. Results: ChatGPT responses were longer than FAQs, with a mean word count of 253.7 vs. 76.6 (difference 177; 95% CI, 151–203) and sentence count of 18.2 vs. 9.0 (difference 9.2; 95% CI, 7.6–10.9). Lexical density was higher by 6.5 percentage points (95% CI, 4.0–9.0), with more characters (0.55; 95% CI, 0.40–0.70) and syllables per word (0.19; IQR, 0.14–0.24). Readability grade levels were consistently higher: Coleman–Liau +3.43, Gunning Fog +3.47, SMOG + 2.96, Flesch–Kincaid +3.61, Automated Readability Index +4.33, and Flesch Reading Ease −20.4 (all p < .05). Stigmatizing term frequency was similar, 0.98 vs. 0.28 per answer (95% CI, −1.3 to +3.3). Discussion: ChatGPT responses were longer and more complex than FAQs, although the frequency of stigmatizing language was similar. Conclusions: ChatGPT produced more comprehensive but less readable content than FAQs, revealing a gap with health literacy standards. While stigmatizing terms were uncommon unless simplified, length and complexity may hinder use. Scientific Significance: Findings quantify readability and stigma trade‐offs in AI‐generated OUD education and emphasize the need for plain language prompting and human review.
- 4 November 2025
- Published by Wiley in The American Journal on Addictions
- Vol. 35 (3) , 362-369
Readability, linguistic complexity, and stigma in ChatGPT responses to opioid use disorder FAQs: A comparative analysis
Background and Objectives: AI chatbots are increasingly used in patient education. For opioid use disorder (OUD), content must be readable and non‐stigmatizing. We compared ChatGPT responses with U.S. health organization FAQs on readability, complexity, and stigma. Methods: We analyzed 50 OUD FAQs paired with ChatGPT GPT‐4o responses. Outcomes included word and sentence counts, lexical density, and six readability indices. Paired differences were tested with t tests or Wilcoxon signed‐rank tests. Results: ChatGPT responses were longer than FAQs, with a mean word count of 253.7 vs. 76.6 (difference 177; 95% CI, 151–203) and sentence count of 18.2 vs. 9.0 (difference 9.2; 95% CI, 7.6–10.9). Lexical density was higher by 6.5 percentage points (95% CI, 4.0–9.0), with more characters (0.55; 95% CI, 0.40–0.70) and syllables per word (0.19; IQR, 0.14–0.24). Readability grade levels were consistently higher: Coleman–Liau +3.43, Gunning Fog +3.47, SMOG + 2.96, Flesch–Kincaid +3.61, Automated Readability Index +4.33, and Flesch Reading Ease −20.4 (all p < .05). Stigmatizing term frequency was similar, 0.98 vs. 0.28 per answer (95% CI, −1.3 to +3.3). Discussion: ChatGPT responses were longer and more complex than FAQs, although the frequency of stigmatizing language was similar. Conclusions: ChatGPT produced more comprehensive but less readable content than FAQs, revealing a gap with health literacy standards. While stigmatizing terms were uncommon unless simplified, length and complexity may hinder use. Scientific Significance: Findings quantify readability and stigma trade‐offs in AI‐generated OUD education and emphasize the need for plain language prompting and human review.